Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af strålebehandling og cemiplimab til mennesker med hudkræft

9. november 2026 opdateret af: Memorial Sloan Kettering Cancer Center

Et fase II, multicenter, enkeltarms klinisk forsøg med stråleterapi og CeMiPlimAb: Rwlc-immunterapi til lokalt avanceret, ikke-operabelt kutan pladecellekarcinom: RAMPART

The purpose of the study is to see if the combination of radiation therapy and cemiplimab immunotherapy is an effective treatment for people with locally advanced, unresectable CSCC.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

34

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • University of Colorado (Data Collection Only)
    • Florida
      • Tampa, Florida, Forenede Stater, 33612
        • Moffitt Cancer Center (Data Collection Only)
    • New Jersey
      • Basking Ridge, New Jersey, Forenede Stater, 07920
        • Memorial Sloan Kettering Cancer Center at Basking Ridge (All Protocol Activities)
      • Middletown, New Jersey, Forenede Stater, 07748
        • Memorial Sloan Kettering Monmouth (All Protocol Activities)
      • Montvale, New Jersey, Forenede Stater, 07645
        • Memorial Sloan Kettering Bergen (All protocol activities)
    • New York
      • Commack, New York, Forenede Stater, 11725
        • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)
      • Harrison, New York, Forenede Stater, 10604
        • Memorial Sloan Kettering Westchester (All Protocol Activities)
      • New York, New York, Forenede Stater, 10065
        • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
      • Rockville Centre, New York, Forenede Stater, 11553
        • Memorial Sloan Kettering Nassau (All protocol activities)
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44195
        • Cleveland Clinic (Data Collection Only)
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19111
        • Fox Chase Cancer Center (Data Collection Only)
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29425
        • Medical University of South Carolina
    • Washington
      • Seattle, Washington, Forenede Stater, 98109
        • University of Washington (Data Collection Only)

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Biopsy proven cutaneous squamous cell carcinoma which is locally advanced

    • Mixed histology tumors that are predominantly squamous cell carcinoma are eligible
    • Locally advanced primary tumor is T3-T4 and/or N+ by AJCC and/or UICC 8th edition clinical criteria
  • T3-T4 primary tumor characteristics noted below:

    • Non-eyelid tumor >4 cm in maximum dimension or with bone erosion or invasion, perineural invasion of nerve 0.1 mm or larger, or invasion beyond subcutaneous fat or >6 mm from granular layer of adjacent normal epidermis
    • Eyelid tumor >2 cm or invading adjacent ocular, orbital or facial structures
  • ≥18 years old

  • Unresectable or medically inoperable according to local multidisciplinary consensus for reasons such as:

    • Tumor or regional lymph node metastases that has recurred despite ≥2 prior surgical procedures, with another curative resection unlikely
    • Tumor or nodal disease with significant local invasion that precludes complete resection
    • Tumor or nodal disease in anatomically challenging area where surgery may result in significant disfigurement or dysfunction (amputation of nose, ear, eye, digit, limb, etc)
    • Medical contraindication to surgery
    • Patient refusal of surgery due to anticipate morbidity
  • ECOG ≤2

  • Adequate bone marrow and metabolic function (by blood tests)

    • Total bilirubin ≤1.5 x upper limit of normal
    • Aspirate aminotransferase (AST) ≤3 x upper limit of normal
    • Alanine aminotransferase (ALT) ≤3 x upper limit of normal
    • Alkaline phosphatase ≤2.5 x upper limit of normal
    • Serum creatinine ≤1.5 x upper limit of normal or estimated creatinine clearance >30 mL/min according to Cockcroft-Gault formula
    • Hemoglobin >9 g/dL
    • Absolute neutrophil count ≥1.5 x10^9/L
    • Platelet count ≥75 x10^9/L
  • Able to provide informed consent

  • Acceptable candidate for curative intent radiotherapy and Cemiplimab immunotherapy, in opinion of radiation and medical oncologist, respectively

  • Life expectancy >18 months

Exclusion Criteria:

  • Primary tumor originating on the mucosal (non-hair bearing) lip or nose, anogenital (penis, scrotum, vulva, perianal) area

  • Iatrogenic immunosuppression (>prednisone 10 mg/day or equivalent within 14 days of initiation of treatment)

  • Women of child bearing potential unwilling or unable to use effective contraception while receiving treatment with cemiplimab and for 4 months thereafter

  • Distant metastases

  • Clinically significant autoimmune disease that requires iatrogenic immunosuppression

    o For example, severe rheumatoid arthritis requiring disease modifying antirheumatic drugs, such as methotrexate

  • Current or previous hematopoietic malignancy (leukemia, lymphoma)

  • Prior allogeneic transplant of solid organ or bone marrow

  • Concurrent malignancies with >10% risk of metastasis or death within 2 years

  • Prior aPD1 immunotherapy or PI3Kδ inhibitor use

  • Prior radiotherapy for the cutaneous squamous cell carcinoma requiring treatment

  • Other ongoing cancer therapy

    o Adjuvant endocrine therapy is permitted for patients with prostate or breast cancer

  • Uncontrolled HIV or infectious hepatitis (viral load detectable in patient with known infection)

  • Pregnancy or breastfeeding

  • Comorbid or diagnostic abnormalities within the last year that would interfere with interpretation of study results

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Participants with locally advanced, unresectable cutaneous squamous cell carcinoma/CSCC

Participants have locally advanced, unresectable cutaneous squamous cell carcinoma/CSCC

Participants will undergo baseline imaging, followed by two doses of neoadjuvant cemiplimab at a dose of 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days). Then, participants will receive concurrent cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) concurrently with RT to 70 Gy in 35 fractions over 7 weeks. Thereafter, participants will receive 38 weeks of cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) for a cumulative total of 12 months of cemiplimab.

Participants will receive radiotherapy to 70 Gy in 35 fractions over 7 weeks concurrently with cemiplimab

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Event Free Survival
Tidsramme: 18 months

The primary endpoint for this study is event free survival at 18 months (week 78 +/- 3 weeks) after starting cemiplimab.

18 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Christopher Barker, MD, Memorial Sloan Kettering Cancer Center

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

6. oktober 2022

Primær færdiggørelse (Anslået)

6. oktober 2027

Studieafslutning (Anslået)

6. oktober 2027

Datoer for studieregistrering

Først indsendt

6. oktober 2022

Først indsendt, der opfyldte QC-kriterier

6. oktober 2022

Først opslået (Faktiske)

10. oktober 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 22-090

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .